Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin pharmacokinetics in stage 4 non-diabetic chronic kidney disease
ACTRN12622001371785Phase 4Terminated
- Sponsor
- University of Otago
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of empagliflozin in chronic kidney disease (CKD), sponsored by University of Otago. Primary endpoint: Empagliflozin pharmacokinetics. Started Jan 2023; status: terminated.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ACTRN12622001371785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001371785.